Taipei, Taiwan, April 10, 2025 —Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company headquartered in Taiwan, today announced its decision to initiate a share buyback program, reflecting its confidence in the company's strong fundamentals and long-term growth potential. Lotus plans to repurchase up to 4 million shares, within a price range of 180 to 245, representing approximately 1.51% of its total outstanding shares, through open market purchases from April 11 to June 9.
Dr. Petar Vazharov, M.D., CEO of Lotus Pharmaceutical, commented:
"We firmly believe that the current share price does not adequately reflect the intrinsic value of Lotus, including our robust fundamentals and promising long-term pipeline. While recent market volatility has been influenced by broader market sentiment and external factors such as tariff-related concerns, we are confident that our sales and profitability will remain unaffected by these policies in the near term. Furthermore, we have implemented comprehensive strategies to mitigate potential risks over the long term. This share buyback represents a strategic opportunity to enhance shareholder value and manage the cost of future equity-based compensation programs."
With a strong balance sheet and healthy cash flow, Lotus is well-positioned to execute this buyback initiative while continuing to invest in strategic priorities. The company remains committed to driving innovation, expanding its product portfolio, and accelerating regional growth.
As part of its continued investment in research and development, Lotus is establishing a new research center in Hyderabad, which will play a critical role in advancing high-value product development and securing a sustainable competitive advantage. Additionally, the company’s recent strategic acquisitions in Southeast Asia have delivered exceptional results, with revenue growth of 500% in Thailand and 800% in Vietnam. These achievements underscore Lotus’s ability to identify and capitalize on high-growth opportunities, and the company remains actively engaged in exploring further mergers and acquisitions to strengthen its market leadership in the region.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness
Media Inquiries:
Yu-ying Yang, Associate Director, Corporate communication.
+886 2 2700 5908
investor@lotuspharm.com